Get App
Last Updated : Apr 05, 2018 05:55 PM IST | Source:

Buy Vivimed Labs Ltd; target of Rs 134: KR Choksey

KR Choksey is bullish on Vivimed Labs Ltd has recommended buy rating on the stock with a target price of Rs 134 in its research report dated March 05, 2018.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

KR Choksey's research report on Vivimed Labs Ltd

Vivimed Labs Limited (VIVIMEDLAB), is an integrated pharma player having a strong presence across the value chain by leveraging its proven expertise in the realm of chemistry. It has a wide portfolio in API, Branded generics and is a a world leader in the development of innovative photochromic dyes. The Company has 11 manufacturing plants (eight domestic and three overseas) across three continents. The pharmaceutical segment contributes 72% to the total sales while the remaining 28% is contributed by the speciality chemical segment.


We value the Company at a P/E multiple of 5x on FY20E and arrive at a target price of INR 134/share resulting into an upside of 76% from the CMP of INR 76/share with valuations subject to re-rating depending upon regulatory hurdles and improvement in operating efficiencies. We assign a “BUY” rating on the stock.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Subscribe to Moneycontrol Pro and gain access to curated markets data, exclusive trading recommendations, independent equity analysis, actionable investment ideas, nuanced takes on macro, corporate and policy actions, practical insights from market gurus and much more.
First Published on Mar 5, 2018 06:13 pm
Follow us on
Available On
PCI DSS Compliant